| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
mTOR signaling pathway (activation)
|
|---|---|
| ln Vitro |
Stable heavy isotopes of hydrogen, carbon, and other elements have been incorporated into drug molecules, largely as tracers for quantitation during the drug development process. Deuteration has drawn attention due to its potential to impact drug pharmacokinetic and metabolic profiles[1].
L-Leucine is an essential branched-chain amino acid (BCAA) that activates the mTOR signaling pathway. As a stable isotope-labeled compound, L-Leucine-13C6 exhibits the same biological activity as unlabeled L-leucine but can be distinguished by mass spectrometry. The 13C labeling allows for precise quantitation of leucine incorporation into proteins and metabolic tracing studies. The compound's ability to activate mTOR makes it useful for studying nutrient sensing and protein synthesis. |
| ln Vivo |
L-Leucine-13C6 is used in SILAC experiments, a mass spectrometry-based technique for quantitative proteomics. The labeled leucine is incorporated into proteins during cell culture, allowing for relative quantitation of protein expression between different experimental conditions. The compound is also used as an internal standard for mass spectrometry-based quantitation of leucine and leucine-containing metabolites in biological samples.
|
| Enzyme Assay |
L-Leucine-13C6 is characterized by isotopic enrichment of 99 atom % 13C. The compound is analyzed by mass spectrometry to confirm isotopic purity and enrichment. The 13C-labeled compound can be distinguished from unlabeled L-leucine by mass shift, enabling accurate quantitation in biological samples.
|
| Cell Assay |
L-Leucine-13C6 is incorporated into cells during SILAC experiments for quantitative proteomics. Cells are cultured in media containing the labeled amino acid, and incorporation is confirmed by mass spectrometry. The labeled leucine is metabolically incorporated into proteins, allowing for identification and quantitation of proteins by mass spectrometry.
|
| Animal Protocol |
In vivo applications of L-Leucine-13C6 include metabolic tracing studies where the labeled amino acid is administered to animals and its incorporation into proteins and metabolites is tracked by mass spectrometry. The compound is used to study protein turnover, amino acid metabolism, and nutrient sensing in vivo. Stable heavy isotopes are incorporated into drug molecules largely as tracers for quantitation during the drug development process.
|
| ADME/Pharmacokinetics |
L-Leucine-13C6 is used as a tracer for quantitation during the drug development process. The stable isotope label allows for precise quantitation by mass spectrometry. The compound has a molecular formula of 13C6H13NO2 and a molecular weight of 137.13. Isotopic enrichment is 99 atom % 13C. The compound is stable and can be stored under standard conditions.
|
| Toxicity/Toxicokinetics |
Toxicological data for L-Leucine-13C6 are derived from the known safety profile of L-leucine, an essential amino acid that is a normal component of the diet. The 13C-labeled form is not expected to have any additional toxicity beyond that of unlabeled L-leucine. Standard laboratory safety precautions should be observed during handling.
|
| References |
|
| Additional Infomation |
L-Leucine-13C6 is a (13)C modified compound.
L-Leucine-13C6 is a stable isotope-labeled amino acid used primarily as a research tool in quantitative proteomics (SILAC) and metabolic tracing studies. The compound is also used as an internal standard for mass spectrometry-based quantitation. Stable heavy isotopes of carbon have been incorporated into drug molecules largely as tracers for quantitation during the drug development process. The compound has an isotopic enrichment of 99 atom % 13C. |
| Molecular Formula |
C6H13NO2
|
|---|---|
| Molecular Weight |
137.1289
|
| Exact Mass |
137.114
|
| CAS # |
201740-84-3
|
| Related CAS # |
L-Leucine;61-90-5
|
| PubChem CID |
71309640
|
| Appearance |
White to off-white solid powder
|
| Density |
1.0±0.1 g/cm3
|
| Index of Refraction |
1.463
|
| LogP |
-1.5
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
9
|
| Complexity |
101
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O[13C]([13C@H]([13CH2][13CH]([13CH3])[13CH3])N)=O
|
| InChi Key |
ROHFNLRQFUQHCH-IQUPZBQQSA-N
|
| InChi Code |
InChI=1S/C6H13NO2/c1-4(2)3-5(7)6(8)9/h4-5H,3,7H2,1-2H3,(H,8,9)/t5-/m0/s1/i1+1,2+1,3+1,4+1,5+1,6+1
|
| Chemical Name |
(2S)-2-amino-4-(113C)methyl(1,2,3,4,5-13C5)pentanoic acid
|
| Synonyms |
L-LEUCINE-13C6
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 7.2924 mL | 36.4618 mL | 72.9235 mL | |
| 5 mM | 1.4585 mL | 7.2924 mL | 14.5847 mL | |
| 10 mM | 0.7292 mL | 3.6462 mL | 7.2924 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Status | Interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT03938870 | Active Recruiting |
Other: L-Leucine 13C6 | Dementia Tauopathies |
Washington University School of Medicine |
August 2015 |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
